Double success for University drug resistance research

Swansea University research into the threat posed by antifungal drug resistance has been highlighted in two prestigious international journals. Fungal disease now kills more people than malaria or TB and the Centre for Disease Control in the USA recognises emergence of multi-drug resistance in fungi as a high level threat.

Dr Josie Parker and Prof Steve Kelly, from Swansea University Medical School's Centre for Cytochrome P450 Diversity have been involved in the studies which investigated different aspects of resistance

The first publication in the American Microbiology Society journal mBio saw them working with fellow academics from the University of Lausanne led by Professor Dominque Sanglard to compare whole genomes to identify key mutations involved in resistance to the drugs available that include azoles, amphotericin B and echinocandins.

A second publication in Nature Communications involved an international collaboration led by Manchester University's Professor Paul Bowyer and Dr Mike Bromley.

It examined drug resistance in the filamentous fungal pathogen Aspergillus fumigatus. Breathing in the airborne spores of this fungus can cause the devastating disease invasive aspergillosis which causes more than 200,000 life-threatening infections every year.

Professor Kelly, who has been researching the field of antifungal resistance for more than 30 years, said: "We are very pleased to be involved in both these research projects and that they have been published in such well-regarded journals.

"Improving our understanding of antifungal drug resistance will help in the development of effective and potentially life-saving therapies for the future."

Abhilash Kannan, Sandra A. Asner, Emilie Trachsel, Steve Kelly, Josie Parker, Dominique Sanglard.
Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae.
mBio Dec 2019, 10 (6). doi: 10.1128/mBio.02512-19.

Takanori Furukawa, Norman van Rhijn, Marcin Fraczek, Fabio Gsaller, Emma Davies, Paul Carr, Sara Gago, Rachael Fortune-Grant, Sayema Rahman, Jane Mabey Gilsenan, Emma Houlder, Caitlin H Kowalski, Shriya Raj, Sanjoy Paul, Peter Cook, Josie E Parker, Steve Kelly, Robert A Cramer, Jean-Paul Latgé, Scott Moye-Rowley, Elaine Bignell, Paul Bowyer, Michael J Bromley.
The negative cofactor 2 complex is a key regulator of drug resistance in Aspergillus fumigatus.
Nat Commun 11, 427 (2020). doi: 10.1038/s41467-019-14191-1.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...